Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial
Barry A. Borlaug(Mayo Clinic), Rickey E. Carter(Mayo Clinic in Florida), A Braun(Mayo Clinic), Yogesh N.V. Reddy(Mayo Clinic), Alessio Alogna(Deutsches Herzzentrum der Charité), Massar Omar(Mayo Clinic), Michael D. Jensen(Mayo Clinic), Dejana Popović(University of Belgrade), Hidemi Sorimachi(Gunma University)
Cited by 116
Related Papers
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
|Journal of the American College of Cardiology|2013|4k
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
|Circulation|2013|2.7k
Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram
|Nature Medicine|2018|1.3k
Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
|Circulation Heart Failure|2010|1.1k
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
|European Heart Journal|2010|1.1k